Bristol-Myers promotes Caforio to COO; Amgen recruits CFO from 3M;

@FiercePharma: Top-read special report Monday: The top 10 pharma companies by 2013 revenue. Feature | Follow @FiercePharma

@TracyStaton: Would you pay $84K for Sovaldi yourself if you had hep C? Check out this discussion. | Follow @TracyStaton

@EricPFierce: New FDA warning letter says Alabama compounder is making sterile drugs in unsanitary facility. More | Follow @EricPFierce

@CarlyHFierce: Allergan spurns Valeant again, but shareholders may have other ideas. Article | Follow @CarlyHFierce

@JustinHFierce: After 7mil US pig deaths from PEDv, Tokyo announces outbreak guidelines on concerns of health-conscious Chinese. Story | Follow @JustinHFierce

> Bristol-Myers Squibb ($BMY) promoted Giovanni Caforio to chief operating officer; he'll add manufacturing and supply-chain duties to his previous role as chief commercial officer. Release

> Amgen ($AMGN) tapped David W. Meline to be SVP and chief financial officer; previously, Meline served in the same roles at 3M Company. Release

> Mylan ($MYL) launched its version of Bristol-Myers Squibb's ($BMY) chemotherapy drug Paraplatin, a treatment for ovarian cancer. Report

> A former SVP at Merck ($MRK) has joined the drug developer Seres as CEO and chairman. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Devicemakers like $MDT, $ABT and $JNJ hold a total of $95 billion offshore--and that's just the tip of the iceberg. Article | Follow @FierceMedDev

@VarunSaxena2: This just in: $MDT will not pursue shareholder complaints against officers, board of directors over Infuse marketing. Filings | Follow @VarunSaxena2

@MichaelGFierce: Mayo Clinic team successfully delivers small molecules to the brain past blood-brain barrier. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: "Hackathons" bring together med tech minds to brainstorm innovative solutions to unmet needs in developing countries. Story from Wired | Follow @EmilyWFierce

> FDA approves Auxogyn embryo test for IVF procedures. Story

> Massachusetts startup develops iOS app for autism. Article

Biotech News

@FierceBiotech: Can Orexigen and its partner Takeda escape the weight-drug jinx? Editor's corner | Follow @FierceBiotech

@JohnCFierce: Still trending: Lilly's head-to-head with Victoza raises a red flag for diabetes drug dulaglutide. Article | Follow @JohnCFierce

@DamianFierce: Theme in $AGN's new slides: $VRX's big rush to do a deal is wild suspicious. More | Follow @DamianFierce

@EmilyMFierce: Compound could delay onset of Type 2 diabetes. FierceBiotech Research story | Follow @EmilyMFierce

> Allergan says no to $53B as Valeant gets hostile. Item

> Receptos shares spike as oral drug reduces brain lesions in PhII MS trial. More

> Dutch biotech arGEN-X plots an IPO as it pads its list of partners. Report

> Analysis: Idenix bidding was competitive, driving up the deal value for an eager Merck. Article

Pharma Manufacturing News

> FDA says compounder making drugs under unsanitary conditions. More

> Drugmaker will use MIT 3-D printing process to make fast-melting capsules. Item

> More consolidation in the API market as Provence picks up peptidemaker Synprosis. Report

> Illinois man pleads guilty to selling $3M worth of foreign Botox. Story

> Roche's Avastin and MabThera are added to list of those stolen in Italy. Article

> Dr. Reddy's avoids pitfalls of Ranbaxy, Wockhardt by cutting workers out of production. More

Biotech Research News

> Compound could delay onset of Type 2 diabetes. Story

> ImStem therapy reverses multiple sclerosis symptoms in mice. More

> Levels of small molecule in brain may indicate depression. Article

> Report: $4.5B needed for BRAIN project through 2025. Item

> Stem cells transplanted successfully in pigs. Story

And Finally... Reset your body clock? Researchers want to test drugs that could make that possible. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.